CEO Exit Adds To Iovance Woes After Cell Therapy Setback
Filing Set Back Until 2022
Iovance has a promising new cancer cell therapy on its hands, but another FDA query and the CEO’s departure has spooked investors.
Iovance has a promising new cancer cell therapy on its hands, but another FDA query and the CEO’s departure has spooked investors.